Empagliflozin effects on iron metabolism as a possible mechanism for improved clinical outcomes in non-diabetic patients with systolic heart failure.
Empagliflozin 對鐵代謝的影響作為改善非糖尿病收縮性心衰竭患者臨床結果的可能機制。
Nat Cardiovasc Res 2024-08-28
Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial.
empagliflozin對心臟衰竭中造血的影響:來自Empire HF試驗的數據。
Eur J Heart Fail 2023-05-01
How can sodium-glucose cotransporter 2 inhibitors stimulate erythrocytosis in patients who are iron-deficient? Implications for understanding iron homeostasis in heart failure.
鈉葡萄糖共同轉運蛋白2抑制劑如何刺激缺鐵患者的紅細胞增多?對於了解心臟衰竭中鐵質平衡的影響。
Eur J Heart Fail 2023-10-12
Empagliflozin suppressed cardiac fibrogenesis through sodium-hydrogen exchanger inhibition and modulation of the calcium homeostasis.
Empagliflozin透過抑制鈉氫交換器和調節鈣平衡,抑制心臟纖維化。
Cardiovasc Diabetol 2023-02-13
Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetes.
心臟和血管血液動力學的變化作為 empagliflozin 在第2型糖尿病中改善心血管和腎臟結果的潛在中介因素。
J Diabetes Complications 2023-09-18
Intravenous iron and SGLT2 inhibitors in iron-deficient patients with heart failure and reduced ejection fraction.
心力衰竭和降低射出分數患者中靜脈注射鐵劑和SGLT2抑制劑的應用。
ESC Heart Fail 2024-03-29
Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2.
Empagliflozin 透過抑制 NHE1-NO 通路來預防心衰竭,與 SGLT2 無關。
Basic Res Cardiol 2024-07-24
Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure: A Validation Cohort of the EMPEROR Program.
心衰竭患者中 SGLT2 抑制伴隨的機制性蛋白質特徵的再確認:EMPEROR 計畫的驗證隊列。
J Am Coll Cardiol 2024-09-01
The effects of SGLT-2 inhibitors on echocardiographic indices and antioxidative properties in patients with heart failure with reduced ejection fraction and diabetes mellitus.
SGLT-2 抑制劑對於心臟射出分數降低及糖尿病患者的超聲心動圖指標和抗氧化特性的影響。
Eur Rev Med Pharmacol Sci 2024-09-04